Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06343714
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-14
Brief Title:
A Study of FB1003 in Healthy Subject
Sponsor:
4B Technologies Limited
Organization:
4B Technologies Limited
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Study to Assess the Safety Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy Subjects
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants Blood tests will be done to examine blood exposure concentration and half-life of FB1003 following administrations For each participant the study will last up to about 12 weeks for single ascending dose part and 18 weeks for multiple ascending dose part including screening
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None